23andMe Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Public

  • Employees
  • 888


  • Stock Symbol
  • ME

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $0.55
  • (As of Monday Closing)

23andMe General Information


23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment include Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.

Contact Information

Formerly Known As
Bleecker Street Acquisition
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Laboratory Services (Healthcare)
Other Industries
Other Devices and Supplies
Information Services (B2C)
Stock Exchange
Corporate Office
  • 349 Oyster Point Boulevard
  • San Francisco, CA 94080
  • United States
+1 (800) 000-0000

23andMe Timeline

Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

23andMe Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.55 $0.59 $0.35 - $2.20 $264M 483M 6.15M -$1.11

23andMe Financials Summary

In Thousands,
TTM 31-Dec-2023 FY 2023 31-Mar-2023 FY 2022 31-Mar-2022 FY 2021 31-Mar-2021
EV 262,325 689,327 1,214,005
Revenue 247,987 299,489 271,893 243,920
EBITDA (511,004) (292,004) (197,547) (165,774)
Net Income (521,968) (311,656) (217,490) (183,619)
Total Assets 608,211 942,598 1,152,068 452,098
Total Debt 78,822 85,304 86,308 93,722
Public Fundamental Data provided by Morningstar, Inc. disclaimer

23andMe Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore 23andMe‘s full profile, request access.

Request a free trial

23andMe Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
% Owned

This information is available in the PitchBook Platform. To explore 23andMe‘s full profile, request access.

Request a free trial

23andMe Comparisons

HQ Location
Total Raised
Post Valuation
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consu
Laboratory Services (Healthcare)
San Francisco, CA
888 As of 2024


se cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non
Hilden, Germany
0000 As of 0000
000.00 0000-00-00


ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate ve
0000 000000000
Fremont, CA
000 As of 0000
00000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

23andMe Competitors (8)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Qiagen Formerly VC-backed Hilden, Germany 0000 00000 000000&0
Personalis Formerly VC-backed Fremont, CA 000 00000 00000000 00000
Promethease Corporate Backed or Acquired 000000&0
OmeCare Formerly VC-backed San Diego, CA 00 00000 000000&0 00000
Mapmygenome Venture Capital-Backed Hyderabad, India 00 00.000 00000 00000 00.000
You’re viewing 5 of 8 competitors. Get the full list »

23andMe Patents

23andMe Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240120028-A1 Learning architecture and pipelines for granular determination of genetic ancestry Pending 05-Oct-2022 000000000
US-20230348604-A1 Antigen binding proteins Pending 29-Apr-2022 00000000000
US-20230220037-A1 Novel use Pending 12-Jan-2022 0000000000
EP-4277609-A1 Inhibitors of trpm3 and their uses Pending 14-Jan-2021 000000000
US-20220115139-A1 Formatting and storage of genetic markers Active 09-Oct-2020 G16B50/30 0
To view 23andMe’s complete patent history, request access »

23andMe Executive Team (51)

Name Title Board Seat Contact Info
Anne Wojcicki Co-Founder, Chief Executive Officer & Chairman
Joe Selsavage Interim Chief Financial Officer & Interim Chief Accounting Officer
Kathy Hibbs JD Chief Administrative Officer, Administration
Reza Afkhami Chief Corporate Development Officer
Jonathan Ward Chief Marketing Officer
You’re viewing 5 of 51 executive team members. Get the full list »

23andMe Board Members (12)

Name Representing Role Since
Anne Wojcicki 23andMe Co-Founder, Chief Executive Officer & Chairman 000 0000
Evan Lovell VG Acquisition Board Member 000 0000
Neal Mohan Self Board Member 000 0000
Patrick Chung JD Xfund Board Member 000 0000
Peter Taylor 23andMe Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

23andMe Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

23andMe Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore 23andMe‘s full profile, request access.

Request a free trial

23andMe Investments & Acquisitions (4)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Lemonaid Health 01-Nov-2021 0000000000 00000 Other Healthcare Services 0000 0000
Orchid (Other Healthcare Technology Systems) 07-Apr-2021 0000 00000 00.00 Other Healthcare Technology Systems
Doctor On Demand 20-Jul-2015 00000 0000 0000 Other Healthcare Services 0000 0000
CureTogether 10-Jul-2012 Merger/Acquisition Decision/Risk Analysis 0000 0000
To view 23andMe’s complete investments and acquisitions history, request access »

23andMe Subsidiaries (1)

Company Name Industry Location Founded
Lemonaid Health Other Healthcare Services San Francisco, CA 0000
To view 23andMe’s complete subsidiaries history, request access »

23andMe ESG

Risk Overview

Risk Rating

Updated December, 01, 2023

21.38 | Med Risk

Risk Scale

A lower score indicates better sustainability












Exposure refers to the extent to which a company is exposed to different material ESG issues



Management is related to actions taken to manage ESG issues


Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.


Covered Companies

00 of 16,421






00 of 928






00 of 407




To view 23andMe’s complete esg history, request access »

23andMe Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
Doctor On Demand 20-Jul-2015 00000 00000 00 0000 Completed
  • 14 buyers
To view 23andMe’s complete exits history, request access »

23andMe FAQs

  • When was 23andMe founded?

    23andMe was founded in 2006.

  • Who is the founder of 23andMe?

    Anne Wojcicki, Paul Cusenza, Linda Avey, and Brian Naughton Ph.D are the founders of 23andMe.

  • Who is the CEO of 23andMe?

    Anne Wojcicki is the CEO of 23andMe.

  • Where is 23andMe headquartered?

    23andMe is headquartered in San Francisco, CA.

  • What is the size of 23andMe?

    23andMe has 888 total employees.

  • What industry is 23andMe in?

    23andMe’s primary industry is Laboratory Services (Healthcare).

  • Is 23andMe a private or public company?

    23andMe is a Public company.

  • What is 23andMe’s stock symbol?

    The ticker symbol for 23andMe is ME.

  • What is the current stock price of 23andMe?

    As of 20-May-2024 the stock price of 23andMe is $0.55.

  • What is the current market cap of 23andMe?

    The current market capitalization of 23andMe is $264M.

  • What is 23andMe’s current revenue?

    The trailing twelve month revenue for 23andMe is $248M.

  • Who are 23andMe’s competitors?

    Qiagen, Personalis, Promethease, OmeCare, and Mapmygenome are some of the 8 competitors of 23andMe.

  • What is 23andMe’s annual earnings per share (EPS)?

    23andMe’s EPS for 12 months was -$1.11.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »